ADC THERAPEUTICS SA (ADCT) Stock Overview
NYSE:ADCT - CH0499880968 - Common Stock
ADCT Key Statistics, Chart & Performance
The current stock price of ADCT is 3.07 USD. In the past month the price increased by 14.13%. In the past year, price increased by 5.86%.
ADCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About ADCT
Company Profile
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 263 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Company Info
ADC THERAPEUTICS SA
Biopole, route de la Corniche 3B
Epalinges VAUD 1066 CH
CEO: Christopher Martin
Employees: 264
Phone: 41216530200
ADC THERAPEUTICS SA / ADCT FAQ
What is the stock price of ADC THERAPEUTICS SA today?
The current stock price of ADCT is 3.07 USD. The price decreased by -5.54% in the last trading session.
What is the ticker symbol for ADC THERAPEUTICS SA stock?
The exchange symbol of ADC THERAPEUTICS SA is ADCT and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is ADCT stock listed?
ADCT stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for ADC THERAPEUTICS SA stock?
12 analysts have analysed ADCT and the average price target is 8.41 USD. This implies a price increase of 174.1% is expected in the next year compared to the current price of 3.07. Check the ADC THERAPEUTICS SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADC THERAPEUTICS SA worth?
ADC THERAPEUTICS SA (ADCT) has a market capitalization of 345.38M USD. This makes ADCT a Small Cap stock.
How many employees does ADC THERAPEUTICS SA have?
ADC THERAPEUTICS SA (ADCT) currently has 264 employees.
What are the support and resistance levels for ADC THERAPEUTICS SA (ADCT) stock?
ADC THERAPEUTICS SA (ADCT) has a support level at 3.02 and a resistance level at 3.26. Check the full technical report for a detailed analysis of ADCT support and resistance levels.
Is ADC THERAPEUTICS SA (ADCT) expected to grow?
The Revenue of ADC THERAPEUTICS SA (ADCT) is expected to grow by 7.51% in the next year. Check the estimates tab for more information on the ADCT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADC THERAPEUTICS SA (ADCT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADCT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADCT, evaluating the profitability, health, valuation and growth aspects
- ADC THERAPEUTICS SA (ADCT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADC THERAPEUTICS SA (ADCT) Sales and EPS estimates to see what analysts future expectations are.
- ADC THERAPEUTICS SA (ADCT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADC THERAPEUTICS SA (ADCT) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADC THERAPEUTICS SA (ADCT) Stock Chart to make your own analysis
- ADC THERAPEUTICS SA (ADCT) Latest news and press-releases to stay up to date.
Does ADC THERAPEUTICS SA (ADCT) stock pay dividends?
ADCT does not pay a dividend.
When does ADC THERAPEUTICS SA (ADCT) report earnings?
ADC THERAPEUTICS SA (ADCT) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of ADC THERAPEUTICS SA (ADCT)?
ADC THERAPEUTICS SA (ADCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.45).
What is the Short Interest ratio of ADC THERAPEUTICS SA (ADCT) stock?
The outstanding short interest for ADC THERAPEUTICS SA (ADCT) is 6.67% of its float. Check the ownership tab for more information on the ADCT short interest.
ADCT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ADCT. When comparing the yearly performance of all stocks, ADCT turns out to be only a medium performer in the overall market: it outperformed 44.4% of all stocks.
ADCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADCT. Both the profitability and financial health of ADCT have multiple concerns.
ADCT Financial Highlights
Over the last trailing twelve months ADCT reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS increased by 43.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADCT Forecast & Estimates
12 analysts have analysed ADCT and the average price target is 8.41 USD. This implies a price increase of 174.1% is expected in the next year compared to the current price of 3.07.
For the next year, analysts expect an EPS growth of 6.78% and a revenue growth 7.51% for ADCT